Tatiana Shelekhova

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

María‐Victoria Mateos, Meletios Α. Dimopoulos, Michèle Cavo et al. · New England Journal of Medicine · 2017 · 949 citations · Full text

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon et al. · The Lancet Oncology · 2014 · 781 citations

Hematological Malignancy, Double-blind Phase 3, Medicine +9

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Michèle Cavo, Joan Bladé et al. · The Lancet · 2019 · 430 citations · Full text

Hematological Malignancy, Overall Survival, Medicine +7

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

Jacob P. Laubach, Fredrik Schjesvold, Mário Mariz et al. · The Lancet Oncology · 2020 · 67 citations

Hematological Malignancy, Oncology, Hematology +8

The impact of <em>ABCB1</em> (rs1045642 and rs4148738) and <em>CES1</em> (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty

Dmitriy Alekseevich Sychev, Tatiana Shelekhova, Kristina Ryzhikova et al. · Pharmacogenomics and Personalized Medicine · 2018 · 49 citations · Full text